These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26162713)

  • 1. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
    Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
    J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.
    Llorens F; Kruse N; Karch A; Schmitz M; Zafar S; Gotzmann N; Sun T; Köchy S; Knipper T; Cramm M; Golanska E; Sikorska B; Liberski PP; Sánchez-Valle R; Fischer A; Mollenhauer B; Zerr I
    Mol Neurobiol; 2018 Mar; 55(3):2249-2257. PubMed ID: 28321768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia.
    Llorens F; Schmitz M; Karch A; Cramm M; Lange P; Gherib K; Varges D; Schmidt C; Zerr I; Stoeck K
    Alzheimers Dement; 2016 May; 12(5):577-89. PubMed ID: 26718584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
    Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
    J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels.
    Lattanzio F; Abu-Rumeileh S; Franceschini A; Kai H; Amore G; Poggiolini I; Rossi M; Baiardi S; McGuire L; Ladogana A; Pocchiari M; Green A; Capellari S; Parchi P
    Acta Neuropathol; 2017 Apr; 133(4):559-578. PubMed ID: 28205010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt-Jakob disease.
    Llorens F; Zafar S; Ansoleaga B; Shafiq M; Blanco R; Carmona M; Grau-Rivera O; Nos C; Gelpí E; Del Río JA; Zerr I; Ferrer I
    Neuropathol Appl Neurobiol; 2015 Aug; 41(5):631-45. PubMed ID: 25134744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
    Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
    PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach.
    Lee SM; Hyeon JW; Kim SJ; Kim H; Noh R; Kim S; Lee YS; Kim SY
    Prion; 2019 Jan; 13(1):141-150. PubMed ID: 31306078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K; Tokutake T; Ishikawa A; Uchiyama T; Tokuda T; Onodera O; Nishizawa M; Ikeuchi T
    J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):608-10. PubMed ID: 20522869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?
    Kapaki E; Kilidireas K; Paraskevas GP; Michalopoulou M; Patsouris E
    J Neurol Neurosurg Psychiatry; 2001 Sep; 71(3):401-3. PubMed ID: 11511720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients.
    Baldeiras IE; Ribeiro MH; Pacheco P; Machado A; Santana I; Cunha L; Oliveira CR
    J Neurol; 2009 Sep; 256(9):1540-50. PubMed ID: 19418113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
    J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
    Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
    Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.
    Koscova S; Zakova Slivarichova D; Tomeckova I; Melicherova K; Stelzer M; Janakova A; Kosorinova D; Belay G; Mitrova E
    Mol Neurobiol; 2017 Oct; 54(8):5919-5927. PubMed ID: 27665282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease.
    Podlesniy P; Llorens F; Golanska E; Sikorska B; Liberski P; Zerr I; Trullas R
    Alzheimers Dement; 2016 May; 12(5):546-55. PubMed ID: 26806388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.